Johnson & Johnson Careers
Head of China, Lung Cancer Initiative
Requisition ID: 1805681211W
At the Janssen Pharmaceutical Companies of Johnson & Johnson, what matters most is helping people live full and healthy lives. We focus on treating, curing and preventing some of the most devastating and complex diseases of our time. And we pursue the most promising science, wherever it might be found.
Janssen Research & Development, LLC discovers and develops innovative medical solutions to address important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Please visit http://www.janssenrnd.com/ for more information.
This position is responsible to lead the China efforts for the Lung Cancer Initiative, which is both a Cross Sector and World Without Disease initiative. Specifically, this individual will be responsible for the development and execution of the China portion of the LCI strategy, which is designed to prevent, intercept and cure lung cancer, creating value for Johnson & Johnson.
The key elements of success for this effort will include developing both a short term and long term China strategy that acknowledges the existing capabilities and resources that exist within the Johnson & Johnson family of companies, while laying out a vision that is integrated with the overall Lung Cancer Initiative strategy. In addition, this will require setting up key external partnerships to execute against this strategy. Specifically, this position will develop early cancer and pre-cancer cohorts to support the development of early detection technologies (eg, imaging based and molecular diagnostics) as well as novel interventions at different points along an individual’s path towards developing a lung cancer. For the latter, this will include forming and/or leading teams that can develop interventions capable of preventing (eg, smoking cessation), intercepting (eg, anti-inflammatories), and curing (medicial device-based interventions) lung cancers in China. It is expected that new processes and procedures will be needed to operate most efficiently in this new paradigm, and this leader will work with J&J Leadership to both develop and execute in this new paradigm.
The successful candidate will develop and continuously refine the Lung Cancer China Strategy. Meet with key internal and external stakeholders to receive input and drive alignment, in conjunction and under the guidance of the overall Lung Cancer Leader.They will identify and manage the LCI China portfolio to deliver against the LCI strategy, both in terms of scientific and commercial expectations. Specifically, the portfolio will include consumer products, pharmaceuticals and/or medical devices. In addition, identify partners that can co-develop, manufacture, and commercialize diagnostics in China to support early detection programs. Recruit and retain top talent to this cause, enabling the delivery of the overall strategy.
In conjunction with the overall LCI leader, will be a key LCI spokesman to help shape the overall LCI efforts as it relates to both LCI as well as the China portion both internally and externally. This may require updates to internal J&J governance teams, as well as additional J&J Internal stakeholders as needed. In addition, this will require shaping this new paradigm in meetings with key regulatory, payor and financial stakeholders.
They will partner w/ key internal stakeholders to develop a best in class ecosystem of innovation partners that will be critical in executing against the overall China strategy. This will be done in partnerships with the WWD Accelerator, J&J Innovation Centers and other key internal stakeholders.
- PhD or MD or equivalent.
- Comprehensive knowledge of biomedical product development in China through proof-of-concept phase.
- Have minimum of 15 years’ experience in disease specific china research, translational medicine as evidenced by peer review publications, patents, leadership in a scientific organization or drug development accomplishments in pulmonary disease.
- May have pharmaceutical, biotech or medical devices experience with a track record of successfully developing a robust product pipeline and portfolio.
- Have operated in a matrix environment and have worked across a complex organization.
- Outstanding communication skills, able to influence and guide without arrogance or ego across multiple functions.
- Have successful managed and developed a team.
J&J (China) Investments Ltd (7046)